McDermott Advises the Shareholders of H-Immune in the Sale of their Shares to HiFibiO
PARIS – McDermott Will & Emery advised H-Immune Therapeutics, a biotechnology company in its development phase and specializing in new therapeutic approaches based on the FULLY HUMAN monoclonal antibodies the field of immuno-oncology, in connection with the sale of their shares to HiFiBio Therapeutics, a pioneer company and one of the world leaders proposing a complete innovative technology creating unparalleled possibilities for the discovery of new therapeutic antibodies against complex targets.
Founded in 2016 by Luc Boblet, former Founder and CEO of PathoQuest and Michel Léonetti, researcher in immunology at the CEA, H-Immune was a pioneer of a unique platform of generation of entirely human antibodies (IVI) based on the in vitro vaccination which completes the unicellular platform of HiFiBio, a world leader, and developed a new pipeline at an early phase through translational collaborations with the principal European cancer treatment centers. After the sale, Mr. Boblet joined the management team of HiFiBio Therapeutics as Head of Development, Executive Vice President.
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,100 lawyers, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, San Francisco, Seoul, Silicon Valley and Washington, DC. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.